Naxitamab

Cat. No.:	HY-P99206
CAS No.:	1879925-92-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1].
In Vitro	Naxitamab (Hu3F8; 72 h) has cytotoxicity against neuroblastoma cell line LAN-1 with an EC_{50} value of 5.1 μg/mL[1]. Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) has antibody-dependent cell-mediated cytotoxic effects (ADCC)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nude mice with LAN-1 xenografts[1]
Dosage:	100 mg/kg
Administration:	Intravenous injection; twice a week, for 4 weeks
Result:	Inhibited tumor growth and prolonged the survival time.

REFERENCES

[1]. Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1;1(4):477-486.

[2]. Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81(2):291-296.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA